Interactive Seminars in Spain and Italy Will Feature Insights into Developments in the Oncology Competitive Landscape
NEW YORK, August 7, 2012—Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, will host Oncology Conference Insight seminars on September 18, 2012, in Madrid and September 20, 2012, in Milan. The seminars will highlight the implications of recent drug approvals and clinical results on the oncology competitive landscape and will offer an opportunity for a candid, mutual exchange of opinions and ideas.
Additionally, we are incorporating qualitative input from KOLs and community oncologists to further validate thoughts on the future of clinical development. Richard Wagner, PhD, Vice President, Kantar Health, will discuss a range of oncology topics, including:
- Colorectal Cancer (CRC): Battle Royale – Best Use of VEGF Pathway Inhibition
- Melanoma: Second Wave and the Rising Tide of Resistance
- Non-Small Cell Lung Cancer (NSCLC): Evolving and Emerging Biomarker Populations
- Ovarian Cancer: The Midas Touch?
- Prostate Cancer: The Rise of Second-Generation Hormone Therapies
Dr. Wagner has broad US and international experience and knowledge in the pharmaceutical and biotechnology markets, complemented by an in-depth clinical and technical subject-matter expertise in oncology. His in-depth knowledge of clinical decisions impacting the commercial success of oncology drugs in development is widely recognized. Dr. Wagner has authored a number of reports on the clinical development of leading pipeline drugs.
The presentations will start at 10:00 am, and Q&A will follow the presentations. To register, download the registration form for the September 18 session in Madrid and the September 20 session in Milan.
About Kantar Health (www.kantarhealth.com)
Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.
With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.
For more information on Kantar Health, please contact Paula Paradise, Vice President of Global Marketing, at email@example.com